Studying how obesity and aging affect metabolism through blood tests
Studies blood markers of aging and metabolism in adults with or without obesity.
Plain-language title generated from the registry record
Registry title: Metabolic Control of Aging and Disease - the MetAGE Deep Phenotyping Cohort
Key facts
- Where
- Graz and Vienna, AustriaSee the 2 sites
Where in Austria
- Medical University of GrazGraz, AustriaTaking people
- Medical University of ViennaVienna, AustriaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Thomas Scherer
- Trial code
- NCT06511297
- Record updated
- 17 February 2026
- Original description
The goal of this prospective observational study is to identify and validate blood based aging biomarkers in relation to cardiometabolic phenotypes of young and old, female and male subjects with or without obesity.Read full original descriptionShow less
Metabolic Control of Aging and Disease - the MetAGE Deep Phenotyping Cohort (Pro-Metage)
The goal of this prospective observational study is to identify and validate blood based aging biomarkers in relation to cardiometabolic phenotypes of young and old, female and male subjects with or without obesity.
The main question is to gain insights into the interaction of obesity related metabolic alteration and aging, and the relevance of loss of metabolic control in the development of age-related diseases in order to build a foundation for targeted drug- and lifestyle interventions in future studies.
Inclusion: Group 1 - Lean, young adults (n = 150); Age 18 - 35 years; Body mass index (BMI) ≥ 18.5 and ≤ 24.9 kg/m2 (≥ 12 months); Group 2 - Overweight, young adults (n = 150); Age 18 - 35 years; BMI ≥ 28kg/m2 (≥ 12 months); Group 3 - Lean, older adults (n = 150); Age ≥ 60 years; BMI ≥ 18.5 and ≤ 24.9 kg/m2 (≥ 3 years); Group 4 - Overweight, older adults (n = 150); Age ≥ 60 years; BMI ≥ 28 kg/m2 (≥ 3 years); Subgroup A (n=75): with pre-existent cardiovascular disease defined as: history of myocardial infarction or evidence of coronary artery disease irrespective of revascularization status or history of ischemic or hemorrhagic stroke or presence of peripheral artery disease or heart failure with preserved ejection fraction (NYHA Class I-II); Subgroup B (n=75): without pre-existent cardiovascular disease; Group 5 - Nonagenerians Age ≥ 90 (n = 50); Age ≥ 90 years; BMI ≥ 18.5 kg/m2 (≥ 3 years).
Exclusion: drug abuse, alcohol > 15 drinks/week; Metal implants that prohibit 3T MRI; drug abuse, alcohol > 15 drinks/week; Metal implants that prohibit 3T MRI; drug abuse, alcohol > 15 drinks/week; Metal implants that prohibit 3T MRI; No previous heart failure, cardiovascular disease, immunosuppressive therapies, chronic inflammatory diseases and active oncologic conditions up until the age of 35 years; drug abuse, alcohol > 15 drinks/week; Metal implants that prohibit 3T MRI; No previous heart failure, cardiovascular disease, immunosuppressive therapies, chronic inflammatory diseases and active oncologic conditions up until the age of 35 years; Metal implants that prohibit 3T MRI; Highly physical active (i.e. > 5 times sporting activity / week with moderate to high intensity [heart rate 140 - 200bpm]); Clinically significant metabolic or endocrine disorders; Heart failure, cardiovascular disease, immunosuppressive therapies, chronic inflammatory diseases and active oncologic conditions; Highly physical active (i.e. > 5 times sporting activity / week with moderate to high intensity [heart rate 140 - 200bpm]); Clinically significant metabolic or endocrine disorders; Heart failure, cardiovascular disease, immunosuppressive therapies, chronic inflammatory diseases and active oncologic conditions; Highly physical active (i.e. > 5 times sporting activity / week with moderate to high intensity [heart rate 140 - 200bpm]); Diabetes, overt hypo/hyperthyroidism; Life-threatening conditions with a life expectancy of less than 1 year or any other condition that would jeopardize proband safety/adherence while participating in this trial; Group 4 - Overweight, older adults (n = 150); Diabetes, overt hypo/hyperthyroidism; Clinically significant cognitive impairment compromising study adherence; Life-threatening conditions with a life expectancy of less than 1 year or any other condition that would jeopardize proband safety/adherence while participating in this trial; Known severe cardiovascular diseases (i.e. PAD IIa or higher, advanced heart failure = left ventricular ejection fraction (LVEF) < 35% or NYHA Class III-IV); Life-threatening conditions with a life expectancy of less than 1 year or any other condition that would jeopardize proband safety/adherence while participating in this trial; Group 5 - "healthy" Nonagenerians Age ≥ 90 (n = 50); Group 1 - Lean, young adults (n = 150); Special diets (i.e. ketogenic diet and time-restricted eating); Claustrophobia; Pregnancy or breastfeeding; Group 2 - Overweight, young adults (n = 150); Special diets (i.e. ketogenic diet and time-restricted eating); Active anti-obesity treatment (e.g. glucagon-like peptide 1 (GLP-1) analogues, polyagonists, naltrexone and bupropion); Claustrophobia; Pregnancy or breastfeeding; Group 3 - Lean, older adults (n = 150); Special diets (i.e. ketogenic diet and time-restricted eating); Claustrophobia; Special diets (i.e. ketogenic diet and time-restricted eating); Active anti-obesity treatment (e.g. GLP-1 analogues, polyagonists, naltrexone and bupropion); Claustrophobia; Claustrophobia.